SLFN11 and small cell lung carcinoma: Recent evidence suggests that SLFN11 protein expression has clinical utility in predicting response to PARP inhibitors: a randomized Phase II study by Pietanza et al. showed that patients with small cell lung cancers expressing SLFN11 had improved progression-free survival (PFS) and (OS) upon treatment with the combination of a PARP inhibitor and the alkylating agent temozolomide [32].